Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-MOG Tregs are an experimental cell therapy consisting of regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) specific for myelin oligodendrocyte glycoprotein (MOG). Developed as a potential treatment for multiple sclerosis (MS), these cells are designed to localize to the central nervous system where MOG is expressed. Upon engagement with MOG, the CAR-Tregs activate and exert localized immunosuppression through the secretion of anti-inflammatory cytokines like IL-10 and TGF-beta, thereby reducing neuroinflammation without the systemic side effects of traditional immunosuppressants. The CAR construct is typically derived from the 8.18 C5 monoclonal antibody clone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAR-MOG Tregs.